

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Assistant Commissioner for Patents  
Washington, D.C. 20231

Atty. Dkt.: CL001188

Date: March 27, 2001

Sir:



03/27/01

Attached for filing is the patent application of:

Inventor: YE et al

Entitled: **ISOLATED HUMAN RAS-LIKE PROTEINS, NUCLEIC ACID  
MOLECULES ENCODING THESE HUMAN RAS-LIKE  
PROTEINS, AND USES THEREOF**

and including attachments as noted below:

☒ Declaration, ☒ Abstract

71 pages of specification; Sequence Listing and claims (including 23 numbered claims), and  
19 sheets of accompanying drawing/s.

☐ Record & return the attached assignment to the undersigned.

☐ Priority is hereby claimed under 35 U.S.C 119 based on the following foreign applications, the entire content of which is hereby incorporated by reference in this application:

Application Number	Country	Day/Month/Year Filed
--------------------	---------	----------------------

, respectively.

☐ Certified copy(ies) of foreign application(s) is/are attached.

☐ Please amend the specification by inserting before the first line --This is a \_\_\_\_\_ of PCT application \_\_\_\_\_, filed \_\_\_\_\_, the entire content of which is hereby incorporated by reference in this application.--

☐ Priority is hereby claimed under 35 U.S.C 120/365 based on the following prior PCT applications designating the U.S., the entire content of which is hereby incorporated by reference in this application:

Application Number	Country	Day/Month/Year Filed
--------------------	---------	----------------------

This application is based on the following prior provisional application(s):

Application No.	Filing Date
-----------------	-------------

respectively, the entire content of which is hereby incorporated by reference in this application, and priority is hereby claimed therefrom.

Please amend the specification by inserting before the first line: --This application claims the benefit of U.S.

Provisional Application No. \_\_\_\_\_, filed \_\_\_\_\_, the entire content of which is hereby incorporated by reference in this application.--

Verified Statement attached establishing "small entity" status (Rules 9 & 27)

The Examiner's attention is directed to the prior art cited in the parent application by applicant and/or Examiner for the reasons stated therein.

Preliminary amendment to claims (attached hereto), to be entered before calculation of the fee below.

Also attached: **Sub of Computer Readable Sequence Listing Diskette**

**FILING FEE IS BASED ON CLAIMS AS FILED LESS ANY HERewith CANCELED**

Basic Filing Fee			\$	710.00
Total effective claims	23	- 20 (at least 20) =	3	x \$ 18.00
			\$	54.00
Independent claims	6	- 3 (at least 3) =	3	x \$ 80.00
			\$	240.00
If any proper multiple dependent claims now added for first time, add \$260.00 (ignore improper)			\$	0.00
			<b>SUBTOTAL</b>	\$ 1004.00
If "small entity," then enter half (1/2) of subtotal and subtract			-\$ (	0.00)
			<b>SECOND SUBTOTAL</b>	\$ 1004.00
Assignment Recording Fee (\$40.00)			\$	0.00
			<b>TOTAL FEE CHARGED TO DEPOSIT ACCOUNT</b>	\$ 1,004.00

Any future submission requiring an extension of time is hereby stated to include a petition for such time extension.

The Commissioner is hereby authorized to charge any deficiency in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our **Account No. 50-0970**. A duplicate copy of this sheet is attached.

CELERA Genomics Corporation  
45 West Gude Drive, C2-4#20  
Rockville, MD 20850  
Telephone # 240-453-3067  
JDK:pdC

CELERA GENOMICS Corporation  
By Atty: Justin D. Karjala, Reg. No. 43,704

Signature: \_\_\_\_\_

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: YE et al

Serial No. To Be Assigned

Filed: March 27, 2001

For: ISOLATED HUMAN RAS-LIKE  
PROTEINS, NUCLEIC ACID MOLECULES  
ENCODING THESE HUMAN RAS-LIKE  
PROTEINS, AND USES THEREOF

Art Unit:

Examiner:

Atty. Docket: CL001188



SUBMISSION OF SEQUENCE LISTING  
UNDER 37 C.F.R. § 1.821(a)

Honorable Commissioner of  
Patents and Trademarks  
Washington, D.C. 20231

Sir:

In compliance with 37 C.F.R. § 1.821(a), applicants submit the Sequence Listing, including the paper copy of the Sequence Listing and the computer readable copy of the Sequence Listing.

**In the Specification:**

The Sequence Listing is provided on pages 55-66 of the specification in the above-identified application.


### REMARKS

In accordance with 37 C.F.R. § 1.821(f), the paper copy of the Sequence Listing and the computer readable copy of the Sequence Listing submitted herewith in the above application are the same.

It is respectfully believed that this application complies with the Sequence Listing requirements and is now in condition for processing.

Respectfully submitted,

CELERA GENOMICS

By:   
Justin D. Karjala  
Reg. No. 43,704

Date: March 27, 2001

Celera Genomics Corporation  
45 West Gude Drive, C2-4#20  
Rockville, MD 20850  
Tel: 240-453-3067  
Fax: 240-453-3084